Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Non-Current Deffered Revenue (2018 - 2021)

TransMedics (TMDX) has 4 years of Non-Current Deffered Revenue data on record, last reported at $1.6 million in Q3 2021.

  • For Q3 2021, Non-Current Deffered Revenue changed 0.43% year-over-year to $1.6 million; the TTM value through Sep 2021 reached $1.6 million, changed 0.43%, while the annual FY2020 figure was $1.6 million, 311.05% up from the prior year.
  • Non-Current Deffered Revenue reached $1.6 million in Q3 2021 per TMDX's latest filing, up from $1.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $3.4 million in Q4 2018 and bottomed at $389000.0 in Q4 2019.
  • Average Non-Current Deffered Revenue over 4 years is $1.3 million, with a median of $1.5 million recorded in 2021.
  • Peak YoY movement for Non-Current Deffered Revenue: tumbled 88.5% in 2019, then skyrocketed 311.05% in 2020.
  • A 4-year view of Non-Current Deffered Revenue shows it stood at $3.4 million in 2018, then crashed by 88.5% to $389000.0 in 2019, then surged by 311.05% to $1.6 million in 2020, then increased by 1.06% to $1.6 million in 2021.
  • Per Business Quant database, its latest 3 readings for Non-Current Deffered Revenue were $1.6 million in Q3 2021, $1.5 million in Q2 2021, and $1.6 million in Q1 2021.